Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. One of the major
clinical challenges is adequate diagnosis and treatment of central nervous system (CNS) …

Simple Summary A bottleneck in oncology is the translation of results from preclinical
models to the clinics. The rate of anticancer drugs that are effective in preclinical studies but …

Acute lymphoblastic leukemia (ALL) is the most common malignant disease affecting
children. Although therapeutic strategies have improved, T-cell acute lymphoblastic …

Antibody-dependent cellular phagocytosis (ADCP) by macrophages, an important effector
function of tumor targeting antibodies, is hampered by 'Don´ t Eat Me!'signals such as CD47 …

Novel immunotherapies have recently led to a broadened spectrum of therapeutic options in
pediatric B-cell precursor acute lymphoblastic leukemia, even in the setting of …

The activating receptor natural killer group 2, member D (NKG2D) represents an attractive
target for immunotherapy as it exerts a crucial role in cancer immunosurveillance by …

Immunotherapy has evolved as a powerful tool for the treatment of B-cell malignancies, and
patient outcomes have improved by combining therapeutic antibodies with conventional …

The microenvironments of leukemia and cancer are critical for multiple stages of
malignancies, and they are an attractive therapeutic target. While skeletal abnormalities are …

Background: Native cluster of differentiation (CD) 19 targeting antibodies are poorly effective
in triggering antibody-dependent cell-mediated cytotoxicity (ADCC) and complement …

Insulin and insulin-like growth factors (IGFs) are mitogenic and prosurvival factors to many
different cell types, including acute lymphoblastic leukemia (ALL). Circulating IGFs are …